News
What are aptamers
The versatility of #aptamers is a quality that makes them an essential
Miguel Moreno, our CSO, has been at CEU
Our CSO, Miguel Moreno, gave a seminar about #aptamer technology
Aptus update the services catalogue for aptamer selection and characterization.
Explore our brochure
Novels incorporations to the AptusBiotech’s Team
Laura Herraiz has joined the team. She is Bachelor in Pharmacy
Present and future on the #aptamer technolgy
In the first issue of #farmabiotec we talk about the
Novels incorporations to the AptusBiotech’s Team
Novels incorporations to the AptusBiotech’s Team: Esther Palacios has joined
AptusBiotech has joined the OLIGOFASTX project
AptusBiotech has joined the OLIGOFASTX project that seeks to develop
AptusBiotech participates in the PHITBAC project
AptusBiotech participates in the PHITBAC project (Nanophotonic biosensors for the
AptusBiotech will participate in the PHITBAC project
AptusBiotech will participate in the PHITBAC project (Nanophotonic biosensors for
Aptamers, What are they for?
Our Scientific Advisor Dr. Víctor M. González from Servicio de
Torres Quevedo 2019 award
The Spanish Ministry of Science and Innovation has awarded Aptus
PREDIAPT Project
Aptus will leader the funded project PREDIAPT. This project is supported
AptaBreast proyect
Aptus will follow their Cancer Treatment program with AptaBreast (RTC2019-007227-1) financed by
Aptus select aptamers against SARSCoV2
#aptamers against receptor binding domain (RBD) of SARS-CoV Spike (S) protein #SARSCoV2 are
Innovation Cheque 2020 for Aptus
Innovation Cheque from Comunidad de Madrid 2020. UCS-Aptameros from IRYCIS-Hospital
Torres Quevedo 2018 award
The Spanish Ministry of Economy and competitivity has awarded Aptus
METASTARG
Aptus Biotech participates since June 2019 of the project METASTARG (TARGETED MULTIFUNCTIONAL NANOEMULSIONS TO
Aptus in Aptamer-Bordeaux
Our staff researcher, Ana Salgado-Figueroa, has participated in Aptamer-Bordeaux with the poster
New Round of Capital Increase
Atpus is attracting novel investments to face the preclinic assays
CAM Doctor Industrial fellowship
Comunidad de Madrid fellows for Industrial PhD. is supporting Ana
Retos Colaboración 2017
El Ministerio de Ciencia Innovación y Universidades ha concedido a
Aptamers against TLR4 to treat stroke
In the project also participate the IRYCIS Aptamer Group, led
Aptus Biotech at 4th Oxford symposium on aptamers
Aptus Biotech, represented by Dr. Ana García-Sacristán, Project Manager at
Aptus paticipa en Programa Retos 2016
El Ministerio de Economía y Competitividad ha concedido a Aptus
ApTOLL recibe financiación del Prgrama Retos 2015
El Ministerio de Economía y Competitividad acaba de conceder a
Caixa Capital apoya a Aptus Biotech
Aptus Biotech ha recibido financiación de Caixa Capital Risc (Capital
Reproducibility crisis: Blame it on the antibodies
«Antibodies are the workhorses of biological experiments, but they are
Aptus recibe financiación del Programa Retos 2014
El Ministerio de Economía y Competitividad ha concedido a Aptus
La plataforma AptaDetect se presenta en Barcelona
Nuestra plataforma biosensora AptaDetect fue uno de los proyectos seleccionados
Aptus en Biospain2014
Aptus Biotech ha participado en el Investment Fórum de Biospain2014 y ha
Aptus con la red temática RiboRed
Como parte de nuestro compromiso en la aportación de nuevas
Aptus participa en RETOS 2014
Aptus Biotech participa en el programa RETOS 2014 del MINECO
Aptus recibe fondos de ENISA
ENISA financia la empresa Aptus Biotech. La agencia pública ENISA
CDTI financia el I + D de Aptus
El CDTI financia las actividades de I+D de Aptus Biotech.
Aptus recibe una ayuda Torres Quevedo
El Ministerio de Economía y Competitividad ha concedido a Aptus
Selección de aptámeros para Leishmania
Investigadores de Aptus Biotech y la Fundación IRYCIS-Ramon y Cajal
Aptus participa en consorcio Europeo
Aptus Biotech participa en un consorcio Europeo para el desarrollo
Ayuda Torres Quevedo para Aptus
El Ministerio de Economía y Competitividad ha concedido a la
Primera ampliación de capital de Aptus
Aptus Biotech ha completado con éxito la primera llamada de